Attached files

file filename
EX-99 - PRESS RELEASE DATED AUGUST 8, 2012 - SAVIENT PHARMACEUTICALS INCrrd353265_38285.htm
EX-99 - TRANSCRIPT DATED AUGUST 8, 2012 - SAVIENT PHARMACEUTICALS INCrrd353265_38284.htm

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  08/08/2012
 
Savient Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
 
Commission File Number:  0-15313
 
DE
  
13-3033811
(State or other jurisdiction of
  
(IRS Employer
incorporation)
  
Identification No.)
 
One Tower Center
East Brunswick, NJ 08816
(Address of principal executive offices, including zip code)
 
732-418-9300
(Registrant’s telephone number, including area code)
 
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 
Item 2.02.    Results of Operations and Financial Condition
 
On August 8, 2012, Savient Pharmaceuticals, Inc. (the "Registrant") announced its financial results for the quarter ended June 30, 2012. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

In addition, also on August 8, 2012, the Registrant held a publicly available live webcast discussion of its financial results for the quarter ended June 30, 2012.   The transcript of the August 8, 2012 conference call is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

 
 
Item 9.01.    Financial Statements and Exhibits
 
See Exhibit Index attached hereto.
 

 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
           
Savient Pharmaceuticals, Inc.
 
 
Date: August 14, 2012
     
By:
 
/s/    Philip K. Yachmetz

               
Philip K. Yachmetz
               
SVP & General Counsel
 
 


 

EXHIBIT INDEX
 
Exhibit No.

  
Description

EX-99.2
  
Transcript dated August 8, 2012
EX-99.1
  
Press Release dated August 8, 2012